# Lilly Agrees KRW 22 Billion Share Investment After Licensing ABL Bio's Grabody

Sang Hoon Lee wanted to take Grabody into a wider range of diseases. Lilly became a research partner in November 2025 and agreed a share subscription two days later; by December the teams were working on multiple candidates.

Canonical: https://kgcf.dsmlholdings.com/insights/abl-lilly-licence-and-equity/
Published: 2026-10-08
Modified: 2026-10-31
Author: [DSML Holdings LLC](https://www.dsmlholdings.com/)

Company: ABL Bio
Event: 2025-11-14
ABL announced the equity agreement on 14 November 2025, following the licence on 12 November; administrative clearance and joint research were reported on 26 December.

## Reported Metrics

- Announced equity investment: KRW 22bn. November agreement amount; December update reports administrative clearance and describes USD 15m equity funding.. [Source 1](https://www.ablbio.com/en/company/news_view/895)

- Referenced licence upfront: USD 40m. Licence upfront referenced in ABL's 14 November 2025 equity announcement.. [Source 1](https://www.ablbio.com/en/company/news_view/895)

ABL Bio announced a Grabody research and licensing alliance with Lilly on 12 November 2025, followed by an equity agreement on 14 November. The collaboration covers multiple therapeutics across modalities and disease areas. In December, Lee reported that administrative procedures were complete and joint candidate research was under way.

The two November decisions joined Lilly to ABL's research in different ways. One commissioned collaborative development using Grabody; the other supported the company doing that work. Lee set out a wider scientific ambition, including obesity, muscle disorders and next-generation ADCs. By December, the teams had begun joint research on multiple candidates.

The funding package combines USD40 million in licence upfront with USD15 million of equity, the latter described in November as approximately KRW22 billion. The licence separately offers up to USD2.562 billion in conditional milestones and net-sales royalties. The share subscription supports ABL's organisation alongside the work commissioned through the research agreement.

## On 12 November, Lilly Licensed Grabody Across a Wider Research Brief

On 12 November 2025, ABL announced a licence, research and collaboration agreement with Lilly. The companies would develop multiple therapeutics across modalities and therapeutic areas using Grabody. Chief executive Sang Hoon Lee linked the agreement to an intention to broaden the platform's indications.

The alliance offered a broader brief than one named candidate. Lee described expanding the modalities to which Grabody could be applied and taking it into areas with substantial unmet need. Obesity and muscle disease were research directions he wanted to pursue, not newly established clinical indications.

That expansion came as another ABL partnership was changing hands operationally. In September, ABL had reported completing a US Phase 1 study of its separate Sanofi-partnered ABL301 in healthy adults and preparing to transfer trial sponsorship. Lee was extending the company's research relationships while its earlier brain-delivery candidate moved towards a partner-led next stage. The Lilly agreement concerned Grabody across therapeutic areas, not simply a second licence to that Parkinson's candidate.

4. [ABL Bio / original 12 November Lilly licence notice and payment conditions](https://ablbio.com/en/company/news_view/896)
1. [ABL Bio / Lilly equity agreement and alliance](https://www.ablbio.com/en/company/news_view/895)
5. [ABL Bio / separate ABL301 Phase 1 completion and planned Sanofi sponsorship transfer](https://www.ablbio.com/en/company/news_view/877)

## Two Days Later, Lilly Agreed to Subscribe for ABL Shares

On 14 November, ABL announced the second agreement: Lilly would subscribe for 175,079 newly issued common shares at KRW 125,900 each. The stated investment was approximately KRW 22 billion. ABL said the price had been calculated under the securities issuance and disclosure rules, with payment expected after HSR and the relevant administrative procedures. A one-year lock-up would run through the Korea Securities Depository.

Lee described the strategic investment as following the licence and said ABL would use the proceeds for Grabody and bispecific ADCs. The one-year lock-up placed the shares alongside a research relationship intended to develop over time. Lilly would participate as a shareholder while the Korean company continued building its own scientific organisation.

Wilson Sonsini advised ABL on the transactions, with technology-transactions lawyers Ian Edvalson and Nguyen Pham working alongside corporate and antitrust teams. Its 18 November account described both the collaborative development and the subscription, with completion still dependent on administrative procedures. The commercial arrangement had to connect technology rights, a Korean share issue and the review required before funding could proceed.

1. [ABL Bio / Lilly equity agreement and alliance](https://www.ablbio.com/en/company/news_view/895)
2. [Wilson Sonsini / participating transaction adviser](https://www.wsgr.com/en/insights/firm-advises-abl-bio-on-strategic-alliance-and-equity-investment-with-eli-lilly.html)

## By December, Joint Candidate Work Was Under Way

On 26 December, Lee said the relevant administrative procedures, including those under the HSR Act, had been completed. ABL announced the USD55 million research-funding package and reported that its scientists and Lilly were already conducting joint research and development on multiple candidates across modalities.

The original licence had linked the USD40 million upfront payment to completion of those procedures. The December announcement says ABL would receive that payment and the equity investment following clearance. The relevant development for the research teams was that the procedural stage had been cleared while their collaborative work was already active.

The update also described research proceeding in parallel inside ABL. Funding would support Grabody, bispecific ADCs and dual-payload ADCs, while clinical immuno-oncology candidates could be extended into combination treatments. Lee was setting priorities for an organisation with several types of experiment and more than one pharmaceutical partner.

3. [ABL Bio / December follow-through, administrative clearance and USD 55m funding](https://www.ablbio.com/en/company/news_view/913)
4. [ABL Bio / original 12 November Lilly licence notice and payment conditions](https://ablbio.com/en/company/news_view/896)

## Lee's Programme Extended Beyond One Disease or One Product

Lee's choices brought together antibody engineering, new therapeutic applications and a broader cancer-research programme. A bispecific antibody can recognise two targets; an ADC couples targeting with a drug payload. His December agenda included developing both bispecific ADCs and dual-payload designs, alongside the continuing Grabody collaboration.

ABL's separate January 2022 Sanofi licence had taken several years to reach its completed initial study. That healthy-adult investigation supported the partner's next development decision, according to Lee's September 2025 account; it did not establish efficacy in Parkinson's disease. The experience shows the longer scientific timetable behind the company's new partnering decisions.

Lilly's November involvement offered Lee another development route and resources for the next set of ideas. The company could pursue an active partner collaboration while continuing work on technologies intended for a wider portfolio. Obesity, muscle disorders and the planned ADC applications still require their own experiments; their significance here is the direction Lee chose for the newly supported research organisation.

The sequence is now more than a prospective investment announcement. Two November agreements were followed by completed procedures and reported joint candidate work in December. For ABL, the partnership added a pharmaceutical research customer that also wanted an interest in the company supplying the technology.

3. [ABL Bio / December follow-through, administrative clearance and USD 55m funding](https://www.ablbio.com/en/company/news_view/913)
1. [ABL Bio / Lilly equity agreement and alliance](https://www.ablbio.com/en/company/news_view/895)
4. [ABL Bio / original 12 November Lilly licence notice and payment conditions](https://ablbio.com/en/company/news_view/896)
5. [ABL Bio / separate ABL301 Phase 1 completion and planned Sanofi sponsorship transfer](https://www.ablbio.com/en/company/news_view/877)

Lilly's dual role gives it an interest in ABL's wider progress, but does not oblige it to advance every candidate. The alliance's scientific outcome remains open even after procedural clearance and the start of joint research.


### Primary Sources

1. [ABL Bio / Lilly equity agreement and alliance](https://www.ablbio.com/en/company/news_view/895) (2025-11-14)

2. [Wilson Sonsini / participating transaction adviser](https://www.wsgr.com/en/insights/firm-advises-abl-bio-on-strategic-alliance-and-equity-investment-with-eli-lilly.html) (2025-11-18)

3. [ABL Bio / December follow-through, administrative clearance and USD 55m funding](https://www.ablbio.com/en/company/news_view/913) (2025-12-26)

4. [ABL Bio / original 12 November Lilly licence notice and payment conditions](https://ablbio.com/en/company/news_view/896) (2025-11-12)

5. [ABL Bio / separate ABL301 Phase 1 completion and planned Sanofi sponsorship transfer](https://www.ablbio.com/en/company/news_view/877) (2025-09-01)
